Drug advertising aimed at consumers, a fast-growing category that reached $4.5 billion last year, will face hard scrutiny in the new Congress, according to industry critics in both the House and Senate. (New York Times, Monday)
Nothing can happen without our representatives' approval.
FEE Timely Classic
Prescription Drugs and Advertising by William L. Anderson